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Type 2 diabetes mellitus is described as a defective action of insulin to 
properly regulate glucose transport within cells and clinically known as insulin 
resistance. Several factors such as elevated free fatty acid, glucocorticoids as well as 
abnormal levels of cytokines have been reported to cause insulin resistance. 
Potentially, phytochemical agents with insulin resistance reverting effect could serve 
as an alternative treatment for type 2 diabetes mellitus. Synacinn™ is a polyherbal 
supplement formulated from Andrographis paniculata, Curcuma xanthorrhiza, 
Cinnamomum zeylanicum, Eugenia polyantha and Orthosiphon stamineous. It is 
claimed as a hypoglycemic agent for diabetes mellitus treatment. Even though the 
anti-diabetes potential of each singular herbs has been well examined, scientific 
evidence has never been reported for polyherbal combination. In this study, the 
potential anti-diabetes mechanism of standardized Syancinn™ was investigated 
using two types of in vitro models; normal and insulin-resistant 3T3-L1 adipocytes. 
It was found that Synacinn™ improved the insulin-mediated glucose utilization in 
both models. For normal adipocytes, the increase of glucose utilization resulted in 
overexpression of glucose transporter 4, insulin receptor 1 and protein kinase B. 
Meanwhile in insulin resistant adipocytes, Synacinn™ increased the glucose 
transporter 4 expression without affecting the insulin receptor 1 and protein kinase B 
expression, indicating that Synacinn™ mechanism of action is dominant on the 
glucose transport rather than repairing the insulin signal transduction. This study also 
shows that Synacinn™ is a mild peroxisome proliferator-activated receptor gamma 
ligand and pro-adipogenic agent. During adipogenesis, Synacinn™ stimulated the 
peroxisome proliferator-activated receptor gamma nuclear transcriptional activity, as 
well as expression of (cytosine-cytosine-adenosine-adenosine-thymidine)-enhancer- 
binding protein alpha, adiponectin, glucose transporter 4 and protein kinase B. In 
terms of safety, standardized Syancinn™ was free from heavy metals and microbial 
contaminations and the concentrations used in the experiment do not affect the 
normal embryogenesis of zebrafish. Collectively, results suggest that Synacinn™ is a 
peroxisome proliferator-activated receptor gamma ligand agent which acted through 
two mechanisms: 1) restores the insulin-mediated glucose utilization by activating 
the glucose transporter 4 expression in insulin resistant adipocytes and 2) enhances 
the adipogenesis into insulin-sensitive adipocytes containing abundance of glucose 
transporter 4 resulted from activation of (cytosine-cytosine-adenosine-adenosine- 
thymidine)-enhancer-binding protein alpha and proliferator-activated receptor 
gamma.
vABSTRAK
Diabetes mellitus jenis 2 digambarkan sebagai kecacatan terhadap tindak 
balas insulin untuk mengawal pengangkutan glukosa di antara sel dan secara klinikal 
dikenali sebagai rintangan terhadap insulin. Beberapa faktor seperti peningkatan asid 
lemak bebas, glukokortikoid serta tahap sitokin yang tidak normal telah dilapor 
menyebabkan rintangan terhadap insulin. Agen fitokimia dengan potensi berbalik 
terhadap kesan rintangan ke atas insulin mampu dijadikan rawatan alternatif 
terutamanya untuk diabetes mellitus jenis 2. Synacinn™ adalah suplemen pelbagai 
herba yang diformulasikan dari Andrographis paniculata, Curcuma xanthorrhiza, 
Cinnamomum zeylanicum, Eugenia polyantha dan Orthosiphon stamineous. Ia 
dikatakan sebagai agen hipoglisemik untuk rawatan diabetes mellitus. Walaupun 
potensi anti-diabetes untuk setiap herba telah pun dikaji dengan terperinci, akan 
tetapi, tiada laporan saintifik yang telah diterbitkan dalam bentuk gabungan pelbagai 
herba. Dalam kajian ini, potensi mekanisma anti-diabetes bagi Synacinn™ yang telah 
dipiawaikan, diselidik menggunakan dua jenis model in vitro; sel lemak normal dan 
sel lemak yang rintang terhadap insulin (3T3-L1). Kajian mendapati bahawa, 
Synacinn™ menambah baik penggunaan glukosa yang didorong oleh insulin di 
dalam kedua-dua model. Bagi sel lemak normal, penigkatan penggunaan glukosa 
menyebabkan ekspresi lebihan pada pengangkut glukosa 4, reseptor insulin 1 dan 
kinase protein B. Manakala bagi sel lemak yang rintang terhadap insulin, Syancinn™ 
meningkatkan ekspresi pengangkut glukosa 4 tanpa mempengaruhi reseptor insulin 1 
dan kinase protein B dan ini menunjukkan bahawa mekanisme tindakan bagi 
Synacinn™ adalah dominan pada pengangkutan glukosa dan bukannya pada 
memperbaiki transduksi isyarat insulin. Kajian juga menunjukkan bahawa 
Synacinn™ adalah ligan reseptor pengaktifan proliferator peroksisom gamma yang 
sederhana dan agen pro-adipogenik. Semasa adipogenesis, Synacinn™ merangsang 
aktiviti transkripsi reseptor pengaktifan proliferator peroksisom gamma nukleus, 
serta ekspresi protein penggalak ikatan alfa (sitosina-sitosina-adenosina-adenosina- 
timidina), adiponektin, pengangkut glukosa 4 dan kinase protein B. Dari segi 
keselamatan, Syancinn™ yang telah dipiawaikan ini adalah bebas daripada 
pencemaran logam berat dan mikrob dan kepekatan yang digunakan dalam 
eksperimen tidak mempengaruhi embriogenesis normal zebrafish. Secara 
keseluruhannya, keputusan menunjukkan bahawa Synacinn™ adalah agen ligan 
reseptor pengaktifan proliferator peroksisom gamma yang bertindak melalui dua 
mekanisma: 1) mengembalikan penggunaan glukosa yang didorong oleh insulin 
dengan mengaktifkan ekspresi pengangkut glukosa 4 didalam sel lemak yang rintang 
terhadap insulin dan 2) meningkatkan adipogenesis kepada sel lemak yang sensitif 
terhadap insulin yang mana mengandungi limpahan pengangkut glukosa 4 hasil 
daripada pengaktifan protein penggalak ikatan alfa (sitosina-sitosina-adenosina- 
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1.1 Background of the Study
Diabetes mellitus (DM) is a metabolic disorder disease. The condition of DM 
is clinically diagnosed by the high level of glucose in circulating blood and known as 
hyperglycemia. It is triggered by insufficient and ineffective insulin actions in 
regulating blood glucose properly. The high glucose level affects several important 
body metabolisms including glucose, proteins and triglyceride metabolism which 
cause kidney and renal failure, heart and cardiovascular disease, blindness and nerves 
degeneration (Katiyar et al., 2015). Clinical investigations have identified several 
factors linked to DM such as autoimmune reactions, hereditary factors, unhealthy 
diet, lack of exercises and overweight. Approximately, 17.5% of Malaysian adults 
above 18 years old were affected by DM in 2015 and the highest among Asian 
countries (Hanum, 2017). In fact, 9.2% of DM patients are unaware of their hidden 
disease (Hanum, 2017). This large-scale epidemic has cost millions of lives 
worldwide and billion dollars for treatments. In Malaysia, our government has to 
spend RM 2684.24 per diabetic patient, while each patient with kidney failure needs 
RM 1400 to RM 3200 monthly for hemodialysis (Hanum, 2017).
DM is categorized into two main groups as clinically manifested. Type 1 
diabetes mellitus (T1DM) or juvenile diabetes is an autoimmune destruction and 
dysfunction of pancreatic beta cells, a specialized cell for insulin production. Patients 
with this type of DM require external insulin injection due to insulin insufficiency. 
Meanwhile for Type 2 diabetes mellitus (T2DM), which comprises 9/10 of total DM
2patients, usually occurs in adults and clinically diagnosed by a high level of blood 
glucose and hemoglobin A1C (HBA1C). However, a recent report had found an 
increasing trend of T2DM among young ages in Japan and USA (Alberti et al., 
2004).
High level of blood glucose in T2DM is caused by the ineffective cellular 
response towards the insulin action. This phenomenon is known as insulin resistance. 
It occurs mainly in insulin-sensitive tissues such as liver, muscles and adipose. In 
insulin resistance cells, it was reported that the defective insulin signaling pathway 
blocked the phosphorylation signals at various steps which subsequently reduced the 
translocation of glucose transporters (Saini, 2010). One of the factors that induced 
the insulin resistance occurrence is glucocorticoids (GCs). GCs such as 
dexamethasone, cortisol and cortisone are clinically used to treat a range of human 
diseases including autoimmune diseases, cancer as well as prevention agent in organ 
transplantation from rejection (Ferris and Kahn, 2012). However, circulated GCs in 
body system also increases the adiposity and enhance the lipolysis, leading to elevate 
of free fatty acid (FFA) and insulin resistance (Lee et al., 2014; Rhee et al., 2004). In 
in vitro models, DEX-induced insulin resistance in adipocytes and muscles cells. It 
was observed that DEX inhibited the activity of downstream cytokines in the insulin 
signaling pathway including phosphatidylinositol 3-kinase (PI3K), protein kinase B 
(AKT), Akt substrate of 160 kDa (AS160) and glucose transporter 4 (GLUT4) 
(Tappy et al., 1994).
Thiazolidinediones (TZDs), an oral anti-diabetes drug class has shown to 
reduce the insulin resistance effect by sensitizing the insulin activity during glucose 
uptake (Arner, 2003). Rosiglitazone and pioglitazone are the examples of TZDs drug 
available in the market. In adipocytes, TZDs acted as peroxisome proliferator- 
activated receptor gamma (PPARy) ligand agent which stimulates the transcription of 
various genes including IRS1, GLUT4, CCAAT-enhancer-binding protein (C/EBPs), 
AKT, PI3K and adiponectin (Cuzzocrea et al., 2004). On other aspects, TZDs also 
enhances the adipogenesis process (Hausman et al., 2008). Adipogenesis is a 
differentiation process of preadipocytes to mature adipocytes which involves changes 
in cells phenotypes and genotypes regulation (Lowe et al., 2011). Replacement of
3enlarging and inflamed adipocytes with small adipocytes has been proposed as an 
alternative method for obesity and anti-diabetes treatment (Muller, 2011).
In search of DM therapeutic drugs, plant derives products have shown 
exciting potential as hypoglycemic agents. In Malaysia, herbal products have become 
the popular alternative for health-promoting supplement with annual income 
approximately RM 17 billion in 2013 and increasing 8-15% each year (Embong, 
2007; Zakaria, 2015). Traditional medicine such as Traditional Chinese Medicine 
(TCM), Ayurvedic and Campa are prepared in a polyherbal mixture containing 
several herbs, spices and plants to enhance the bioactive effectiveness as well as 
eliminate undesired adverse events (Katiyar et al., 2015; Yeo et al., 2011). There are 
various polyherbal formulations have been developed to treat DM including Diabe 
Diabet, Diabecon, Diabeta, Diakyur, Diasulin, Dihar Dihar, DRF/AY/5001, 
ESF/AY/500, 5EPHF, Karmin Plus, Okudiabet, PM021 (Katiyar et al., 2015).
1.2 Problem Statem ent
Despite the advanced research in drugs development, DM therapies require 
lifelong drugs consumption to control the glycemic condition at a normal level. 
Various oral therapeutic drugs for T2DM are available in market such as metformin, 
sulphonylureas, and alpha-glucosidase inhibitors with a specific mechanism of action 
and site of action (Moller, 2001). Unfortunately, these drugs have limitations and 
unwanted side effects (Chaudhury et al., 2017; Kumar et al., 2016). For example, 
metformin increases glucose uptake in body tissues and inhibits gluconeogenesis in 
liver but it is an appetite suppressant and not suitable for patients with liver and 
kidney problems (The Diabetes Prevention Program Research, 2012). Meanwhile for 
sulphonylureas, an insulin release stimulator, only suitable for T2DM patients (Kalra 
et al., 2015). Potentially, natural therapies derived from plants (single compounds, a 
group of compounds or whole extract) have become an alternative choice to reduce 
and prevent DM traditionally (Katiyar et al., 2015; Prabhakar and Doble, 2011).
4Synacinn™, a traditional supplement has been recommended for treatment of 
DM. Its testimonials claimed to reduce DM related signs including tiredness and high 
blood glucose level. Synacinn™ is formulated from a combination of five Malaysian 
herbs including Andrographis paniculata, Curcuma xanthorrhiza, Cinnamomum 
zeylanicum, Eugenia polyantha and Orthosiphon stamineous. Even though there are 
various reports regarding the anti-diabetes potential of each single herbs, but there is 
no scientific reports have been published for polyherbal combination. It is believed 
that the synergistic effect of this combination involved multiple mechanisms 
ultimately covering all possible effects of DM in our body. Hence, the recent 
challenge is to identify and understand the mechanism of action of Synacinn™ at 
cellular levels in treating DM. Insulin-sensitive 3T3-L1 adipocytes were employed as 
DM in vitro model due to the important roles on glucose metabolism and insulin 
signaling pathway.
1.3 Research Questions
To accomplish the proposed study, several questions need to be answered:
i. What are the concentrations of phytochemicals in Synacinn™?
ii. How Synacinn™ reduces the insulin resistance effect?
iii. Does Synacinn™ produce similar effect as PPARy ligand on the development
of adipocytes?
1.4 Objectives of the Study
i. To establish the quality control and safety endpoints of Synacinn™.
ii. To evaluate the possible anti-diabetes mechanism of Synacinn™ on insulin- 
resistance 3T3-L1 adipocytes specifically for the glucose transport and 
insulin signaling pathway.
iii. To investigate PPARy ligand activity on the development of adipocytes.
51.5 Scopes of the Study
Herbal product is composed of multiple bioactive compounds which act 
synergistically to improve human health. Poor quality control (QC) especially on the 
raw materials and the manufacturing process will result in variation between batches 
and possible contamination from hazardous compounds, microbes and heavy metals. 
Hence, strict QC is imperative to control and standardize the herbal-based 
production. 3T3-L1 preadipocytes can be differentiated to adipocytes by suitable 
hormones. Once differentiated, it is sensitive to insulin and play important role in 
insulin pathway and glucose metabolism (Gregoire et al., 1998; Medina-Gomez et 
al., 2007; Ntambi and Young-Cheul, 2000). Several scopes were identified based on 
the Synacinn™ QC aspects as well as adipocytes capability in order to achieve the 
proposed objectives.
i. Quality control of phytochemicals in the water extract of Synacinn™ using 
Fourier Transmission Infra-Red Spectroscopy (FTIR), Gas Chromatography 
-  Mass Spectroscopy (GC-MS) and High Performance Liquid 
Chromatography (HPLC).
ii. Adipocytes were treated with dexamethasone to induce insulin resistance 
condition. Synacinn™ effect on this model is assessed based on the glucose 
utilization capacity and the restoration of impaired insulin signaling pathway.
iii. Adipogenesis of 3T3-L1 preadipocytes can be induced by chemical cocktail. 
The modulation effect of Synacinn™ on the adipogenesis was measured by 
quantifying the lipid droplet formation, intracellular triglyceride and 
adipokines expression using immunoblotting and transcription assay.
1.6 Significance of the Study
1. Provides the first possible mechanism of action of Synacinn™ for a better 
understanding on how it works as anti-diabetes supplement.
2. Leads to further preclinical and clinical tests on higher models.
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